Key result
Post-discharge apixaban linked to ~36% lower 90-day VTE risk vs no prophylaxis, without excess bleeding.
Why the study?
Post-discharge VTE chemoprophylaxis after metabolic and bariatric surgery is variably implemented, and the optimal pharmacologic agent and dosing regimen remain unclear.
Does post-discharge VTE chemoprophylaxis reduce VTE events in adult patients undergoing primary sleeve gastrectomy or Roux-en-Y gastric bypass?
Cohort (n=275,843)
Yes
Does post-discharge VTE chemoprophylaxis reduce VTE events in adult patients undergoing primary sleeve gastrectomy or Roux-en-Y gastric bypass?
Odds Ratio: 0.64 (95% CI 0.42–0.98)
Absolute Event Rate: 0.41% vs 0.64%
Number Needed to Treat: 442
p-value: p=0.050
Post-discharge VTE chemoprophylaxis with apixaban, rivaroxaban, or enoxaparin is associated with a reduced 90-day VTE risk without significantly increasing bleeding in bariatric surgery patients.
No takes yet. Share an insight, caveat, or question.
May warrant post-discharge prophylaxis consideration in bariatric surgery; leaves open need for RCTs before practice change.
Gillikin et al. (2026) conducted a cohort in Post-discharge venous thromboembolism after metabolic and bariatric surgery (n=275,843). Post-discharge apixaban 2.5 mg twice daily vs. No post-discharge prophylaxis was evaluated on Venous thromboembolism (VTE) incidence through 90 postoperative days (propensity score-matched analysis) (OR 0.64, 95% CI 0.42-0.98, p=0.050). Post-discharge prophylaxis with apixaban 2.5 mg twice daily reduced 90-day VTE incidence compared with no prophylaxis (0.41% vs 0.64%, OR 0.64) in propensity score-matched analyses, without significantly increasing bleeding.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: